Zoetis Inc. (NYSE:ZTS) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, Stifel ...

I remain positive on Phibro's long-term prospects and would look to buy on dips, as structural improvements appear ...

Zoetis was created in 2013 after splitting off from Pfizer’s animal health division. While it may not seem like a household ...

Infosys has announced a strategic partnership with Zoetis to enhance the latter's IT operations using AI and automation. This ...

Infosys partners with Zoetis to enhance digital capabilities in animal health industry, focusing on AI solutions and ...

Infosys is expected to improve Zoetis’ operational efficiency and help the former with its long-term business objectives.

U.S. equities rose at midday ahead of the latest announcement from the Federal Reserve, as President Donald Trump again ...

Editor’s note: This interview has been edited for length and clarity.

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal ...

Zoetis published its 2024 Sustainability Progress Update "Advancing Sustainability in Animal Health for a Better Future" to ...

Zoetis Inc. closed 19.30% below its 52-week high of $200.33, which the company achieved on September 19th.

Zoetis Inc. closed 17.97% short of its 52-week high of $200.33, which the company reached on September 19th.